In an interview with Takeda’s President of Emerging Markets Business Unit, Giles Platford portrays a vitalized focus on emerging markets and explains why those countries are positioned as one of three key growth drivers for the company. With Takeda’s recently unveiled Access-to-Medicines (AtM) strategy, he also characterizes the role of pharmaceutical innovators bridging access to potentially life-saving therapies for patients.
As an industry, one of the key challenges we face is how to address access and affordability for our innovative products in a sustainable way, and this is why we recently launched our Access to Medicines (AtM) strategy. It aims to address multiple access barriers common across regions such as South-East Asia, Latin America and Sub-Saharan Africa
